Company news
Arrowhead Pharmaceuticals, Inc. news in 2024
Arrowhead Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
December 22, 2024
Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases
December 10, 2024
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
December 2, 2024
Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences
December 1, 2024
Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results
November 25, 2024
Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs
November 25, 2024
Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
November 17, 2024
Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran
November 17, 2024
Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results
November 4, 2024
Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences
November 3, 2024
Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome
October 31, 2024
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
September 22, 2024
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran
September 9, 2024
Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
September 1, 2024
Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
August 20, 2024
Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies
August 13, 2024
Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results
August 7, 2024
Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street
August 7, 2024
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results
July 23, 2024
Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
June 24, 2024
Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
June 23, 2024
Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
June 2, 2024
Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
May 30, 2024
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia
May 28, 2024
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
May 27, 2024
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
May 19, 2024
Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
May 8, 2024
Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
May 1, 2024
Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
April 28, 2024
Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
April 25, 2024
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
April 23, 2024
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
April 23, 2024
Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
April 6, 2024
Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
March 24, 2024
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
March 7, 2024
Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
March 3, 2024
Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results
February 5, 2024
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results
January 21, 2024
Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million
January 4, 2024
Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock
January 2, 2024
Calls in 2024
- Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q4 2024 Earnings Call
Nov 26, 2024
Transcript - Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q3 2024 Earnings Call
Aug 8, 2024
Transcript - Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q2 2024 Earnings Call
May 9, 2024
Transcript - Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q1 2024 Earnings Call
Feb 6, 2024
Transcript
Decks in 2024
- Complement Based Drug Development Summit 2024
Conference · 20 slides · Dec 11, 2024
- Technical Presentation (October 2024)
Technical · 68 slides · Oct 7, 2024